nayana-c1.867c992ae9100904cc61c84591adf0f8f863e0387e30f0d0dbc86640e9f50a1a.en.test.21537

The task

What is the co-primary efficacy endpoint that the revised sample size of 2160 patients would allow detecting? A. a difference of 0.03 points on the EQ-5D-3L overall health utility score B. a reduction in absolute risk of 5% C. an increase in glomerular filtration rate by 30 mL/min/1.73m² D. a decrease in creatin kinase concentration by 570 U/L Return only the single uppercase letter of the correct option.